HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results Life Science Investing
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License Biotech Investing
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Life Science Investing
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Pharmaceutical Investing
Rain Enhancement Technologies Reports Consistent Snowpack Enhancement Across Three-Month Winter Operations in Utah Life Science Investing
Ocumetics Technology Corp. Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design Technology Investing
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 , a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease Life Science Investing
